Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Exercise program for patients with cardiac amyloidosis

Official title: Pilot Study Evaluating Supervised Cardiac Rehabilitation in Patients With Cardiac Amyloidosis

Run by Wake Forest University Health Sciences · NCT06096675 · Data updated 2026-11-12

This study tests whether a supervised exercise program can help people with cardiac amyloidosis and heart failure feel better and improve their heart health.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment50 (estimated)
SponsorWake Forest University Health Sciences
Academic / other
Locations1 site (Charlotte, North Carolina)
StatusRecruiting
StartedJanuary 22, 2024
Main results expectedDecember 2027
Study endsDecember 2027
Registry record updatedJuly 21, 2026
Trial IDNCT06096675 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults over 18 with NYHA Class I-III heart failure who are stable on treatment for cardiac amyloidosis.

Probably not a fit

Patients with NYHA Class IV heart failure or significant comorbidities that affect their ability to participate may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effects of a supervised exercise program on patients with cardiac amyloidosis and heart failure with preserved ejection fraction (HFpEF). The Atrium Health cardiac rehabilitation program aims to improve cardiac performance and quality of life through structured exercise sessions. Participants will engage in three one-hour sessions per week for 12 weeks, focusing on enhancing their cardiorespiratory fitness. The study seeks to gather objective data to potentially expand cardiac rehabilitation eligibility for cancer patients in the future.

Why it matters

Potential benefit: If successful, this program could significantly improve the quality of life and cardiac function for patients with cardiac amyloidosis.

How similar studies have gone: Other studies have shown positive outcomes with supervised exercise programs in heart failure patients, suggesting a promising approach for this population.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age \> 18
* New York Heart Association (NYHA) Class I-III Heart Failure
* Able to Exercise
* On stable treatment for their cardiac amyloidosis or under active surveillance
* Life expectancy of at least 6 months
* Ability to understand and the willingness to sign a written informed consent document in English, and the willingness/ability to comply with the protocol activities
* Participant must be able and willing to follow the cardiac rehabilitation activities

Exclusion Criteria:

* Inability to provide informed consent
* Inability to commit to in-person supervised exercise sessions for three one-hour sessions a week for 12 weeks
* NYHA Class IV Heart Failure
* Pulmonary disease requiring home oxygen
* Gait instability or history of prior falls
* In the opinion of the Principal Investigator, have a clinically significant comorbid disease that is likely to affect the ability of the patient to complete the trial, interfere with their ability with measurement of self-reported outcomes.

Where it's running

  • Sanger Heart and Vascular Institute
    Charlotte, North Carolina, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.